Clinical Trial Update: Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent [Phase 2]

View source ↗

Summary

Phase 2 ascending-dose study of RVP-001, a manganese-based MRI contrast agent, completed to assess safety and preliminary efficacy in CNS lesions and brain tumo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acoustic Neuroma
• Brain Metastases
• Brain Neoplasms
• Glioma
• Meningioma
• Multiple Sclerosis
• Neurofibroma
• Schwannoma

Drugs mentioned

• RVP-001 (RVP-001 manganese-based MRI contrast agent)

Snippet

Sponsor: Reveal Pharmaceuticals Inc. | Conditions: Central Nervous System (CNS) Lesions, Brain Metastases | Phase 2 | Status: COMPLETED